Company Description
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture.
The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support.
It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization.
The company serves biotechnology and biopharmaceutical industries.
The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018.
Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
Country | United States |
IPO Date | Apr 4, 1994 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 371 |
CEO | Nicholas Stewart Green B.Sc., MBA |
Contact Details
Address: 2642 Michelle Drive Tustin, California United States | |
Website | https://www.avidbio.com |
Stock Details
Ticker Symbol | CDMO |
Exchange | NASDAQ |
Fiscal Year | May - April |
Reporting Currency | USD |
CIK Code | 0000704562 |
CUSIP Number | 05368M106 |
ISIN Number | US05368M1062 |
Employer ID | 95-3698422 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Nicholas Stewart Green B.Sc., MBA | President, Chief Executive Officer & Director |
Daniel R. Hart | Chief Financial Officer |
Mark R. Ziebell J.D. | Vice President, General Counsel & Corporate Secretary |
Matthew R. Kwietniak | Chief Commercial Officer |
Richard A. Richieri | Chief Operations Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Dec 10, 2024 | 10-Q | Quarterly Report |
Dec 10, 2024 | 8-K | Current Report |
Dec 03, 2024 | PREM14A | Filing |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 07, 2024 | DEFA14A | Filing |
Nov 07, 2024 | DEFA14A | Filing |
Nov 07, 2024 | 8-K | Current Report |
Oct 17, 2024 | 8-K | Current Report |